SVB Leerink Boosts Danaher (NYSE:DHR) Price Target to $280.00

Danaher (NYSE:DHR) had its target price boosted by SVB Leerink from $275.00 to $280.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has an outperform rating on the conglomerate’s stock.

Several other equities research analysts have also commented on the company. Bank of America upped their price target on Danaher from $270.00 to $275.00 and gave the stock a neutral rating in a research note on Wednesday. TD Cowen boosted their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock a buy rating in a research note on Wednesday. Barclays increased their price objective on shares of Danaher from $260.00 to $270.00 and gave the stock an equal weight rating in a research report on Wednesday, April 24th. Robert W. Baird lifted their target price on shares of Danaher from $259.00 to $271.00 and gave the company an outperform rating in a report on Wednesday, April 24th. Finally, HSBC raised Danaher from a hold rating to a buy rating and raised their price objective for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Six investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of Moderate Buy and an average target price of $276.88.

Danaher Trading Up 1.5 %

NYSE DHR opened at $274.13 on Wednesday. The company has a market cap of $197.98 billion, a P/E ratio of 46.46, a P/E/G ratio of 4.11 and a beta of 0.83. Danaher has a 12 month low of $182.09 and a 12 month high of $277.72. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.51. The company has a 50-day moving average of $255.16 and a 200-day moving average of $249.09.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. Danaher’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter last year, the business earned $2.05 EPS. As a group, equities analysts predict that Danaher will post 7.6 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, July 26th. Investors of record on Friday, June 28th were paid a $0.27 dividend. The ex-dividend date of this dividend was Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Activity at Danaher

In other news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares in the company, valued at approximately $28,304,483.16. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the transaction, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Rainer Blair sold 19,085 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $255.00, for a total transaction of $4,866,675.00. Following the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at approximately $29,578,725. The disclosure for this sale can be found here. Insiders sold a total of 84,775 shares of company stock valued at $21,802,690 over the last three months. 11.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DHR. Cape Investment Advisory Inc. acquired a new position in Danaher during the 4th quarter valued at about $25,000. Tsfg LLC grew its position in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher during the 2nd quarter valued at about $25,000. Wetzel Investment Advisors Inc. acquired a new stake in shares of Danaher in the 4th quarter worth approximately $29,000. Finally, Redmont Wealth Advisors LLC bought a new position in shares of Danaher in the first quarter valued at approximately $30,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.